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Abstract 
Conventional photodynamic therapy (PDT)’s clinical application is limited by depth of penetration by 
light. To address the issue, we have recently developed X-ray induced photodynamic therapy (X-PDT) 
which utilizes X-ray as an energy source to activate a PDT process. In addition to breaking the shallow 
tissue penetration dogma, our studies found more efficient tumor cell killing with X-PDT than with 
radiotherapy (RT) alone. The mechanisms behind the cytotoxicity, however, have not been elucidated. 
In the present study, we investigate the mechanisms of action of X-PDT on cancer cells. Our results 
demonstrate that X-PDT is more than just a PDT derivative but is essentially a PDT and RT 
combination. The two modalities target different cellular components (cell membrane and DNA, 
respectively), leading to enhanced therapy effects. As a result, X-PDT not only reduces short-term 
viability of cancer cells but also their clonogenecity in the long-run. From this perspective, X-PDT can 
also be viewed as a unique radiosensitizing method, and as such it affords clear advantages over RT in 
tumor therapy, especially for radioresistant cells. This is demonstrated not only in vitro but also in vivo 
with H1299 tumors that were either subcutaneously inoculated or implanted into the lung of mice. 
These findings and advances are of great importance to the developments of X-PDT as a novel 
treatment modality against cancer. 
Key words: photodynamic therapy; radiotherapy; lung cancer; clonogenecity; nanoparticles. 
Introduction 
PDT is a relatively new and minimally invasive 
cancer therapy approach [1-3]. PDT utilizes 
photosensitizers that are activated by light in the 
presence of oxygen, producing reactive oxygen 
species (ROS) that are cytotoxic [3]. PDT can kill 
cancer cells directly and or damage tumor 
microvessels, leading to tissue ischemia [2, 4, 5]. It has 
been utilized in the clinic for treatments of different 
cancer types, including esophageal cancer, non-small 
cell lung cancer, bladder cancer, and head and neck 
cancer [6-10]. Despite of the promises, however, PDT 
suffers from the shallow tissue penetration of light, 
especially in the visible spectrum window [11]. There 
has been progress of developing near-infrared (NIR) 
photosensitizers, for instance Lumin, Motexafin 
lutetium, and TOOKAD (absorption peaks at 770 nm, 
732 nm and 753 nm) [12, 13]. However, even in the 
NIR region, light can travel less than 1 cm in tissues. 
This restriction has largely limited the applications of 
PDT in the clinic.  
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Recently, we and others have developed a new 
PDT derivative called X-ray induced PDT, or X-PDT 
[14-17]. The goal is to break the shallow penetration 
restriction by using X-ray as an energy source [18]. 
The idea of utilizing X-ray to overcome the shallow 
penetration of PDT was first raised by Chen et al. in 
2006 [19], but it was not until very recently that we 
and the Chen group demonstrated its feasibility in 
vivo [14-17]. In particular, we showed in a recent 
study that SrAl2O4:Eu2+ nanoparticle (SAO:Eu, a 
scintillator which convert X-ray photons to visible 
photons) and MC540 (a photosensitizer with 
matching excitation wavelength) co-loaded 
mesoporous silica nanoparticles 
(MC540-SAO:Eu@mSiO2) can produce singlet oxygen 
(1O2) under X-ray radiation, leading to efficient cancer 
cell death, even when the cells are beneath thick 
tissues [14]. 
It is clear that during X-PDT, not all X-ray 
energy, but a portion of it, is converted to visible 
photons to activate PDT. Despite of the studies by us 
and others observed enhanced treatment efficacy with 
X-PDT relative to radiation therapy (RT) alone at the 
same radiation doses [14-17], this phenomenon is 
intriguing, indicating that there is more to X-PDT than 
a mere PDT process. In the current study, we tap into 
the mechanisms behind X-PDT-induced cell death. 
Specifically, we conducted comprehensive studies to 
examine the impacts of X-PDT on cell viability, 
clonogenicity, apoptosis, necrosis, DNA damage, and 
membrane lipid damage. Our studies showed that 
X-PDT contains a RT component, and hence it is 
essentially a RT and PDT combination. The two 
modalities interplay to attack both cell membrane and 
DNA, leading to lethal damage that is beyond the 
repairs of cells. The synergy explains the better cell 
killing efficacy of X-PDT than RT, even for cells that 
are refractory to radiotherapy. In particular, we found 
that X-PDT can efficiently kill H1299 cells, which are 
radioresistant non-small cell lung cancer (NSCLC) 
cells. The enhanced efficacy was observed not only in 
vitro but also in vivo with a subcutaneous tumor 
model or when H1299 cells were percutaneously 
implanted into the lung. These findings are of great 
value to our understanding of X-PDT as a novel 
treatment modality and its further transformation for 
eventual clinical translation.  
Results 
Preparation of MC540-SAO:Eu@mSiO2 
nanoparticles 
The MC540-SAO:Eu@mSiO2 nanoparticles were 
prepared by following our published protocol [14]. 
Briefly, SrCO3, Al2O3, Eu2O3 and graphite powders 
were mixed and heated in a tube furnace at 1450 °C 
for 2 h under an argon flow. The pressure was 
maintained at 5 Torr. The as-synthesized bulk SAO:Eu 
was subject to mechanical grinding, followed by 
sedimentation, filtration and centrifugation, to yield 
nanoscale nanoparticles (73.5 ± 26.9 nm, Figure 1a&b). 
 
Figure 1. Characterizations of SAO:Eu@mSiO2 nanoparticles. (a) TEM image of SAO:Eu nanoparticles. (b) TEM image of a representative SAO:Eu@mSiO2 nanoparticle. (c) 
XEOL spectrum of SAO:Eu@mSiO2 nanoparticles and the absorption spectrum of MC540. The excitation wavelength of photosensitizers and the emission wavelength of SAO:Eu 
match well. (d) Singlet oxygen generation under X-ray irradiation. (e) Cytotoxicity of SAO:Eu@mSiO2 nanoparticles. Little toxicity was observed even at high nanoparticle 
concentrations. 
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X-ray diffraction (XRD) analysis found that the 
composition of the material was monoclinic SrAl2O4 
(JCPDS #74-0794, Figure S1). Inductively coupled 
plasma (ICP) confirmed the chemical composition 
and found that Eu accounts for ~1% of the total mass. 
As described in the previous study, SrAl2O4:Eu can be 
stimulated by both Uv-vis and X-ray to emit green 
photoluminescence (centered at ~520 nm, Figure 1c), 
which is attributed to 4f65d1→4f7 transition of Eu2+ 
ions [15].  
SrAl2O4:Eu is a highly hydrolytic material and is 
quickly reduced to constituent ions in an aqueous 
solution [15]. For bio-applications, we coated 
SrAl2O4:Eu nanoparticles with two layers of silica 
(Figure 1b). These include an inner, solid silica layer 
that prevents direct contact with the aqueous 
surroundings, and an outer, mesoporous silica layer 
that provides a docking place for photosensitizers 
[14]. Into the resulting SrAl2O4:Eu@mSiO2 
nanoparticles, MC540 (Figure S2), a common 
photosensitizer that has been investigated in both 
pre-clinical and clinical studies [20], was loaded. The 
absorbance wavelengths of MC540 well match the 
emission wavelengths of SAO:Eu (Figure 1c, Figure 
S3). Using singlet oxygen sensor green (SOSG) assays, 
we studied the ability of X-PDT to producing 1O2. It 
was found that X-ray alone (1-4 Gy) was not able to 
produce 1O2, either with PBS, MC540, or SrAl2O4:Eu 
nanoparticles (Figure 1d). As a comparison, when 
both SrAl2O4:Eu@mSiO2 (0.05 mg/mL) and X-ray 
were applied, efficient 1O2 production was observed 
(Figure 1d).  
Impact of X-PDT on cell viability and 
clonogenecity 
We first investigated the impact of X-PDT on cell 
viability by MTT assays. Radioresistant NSCLC 
H1299 cells were used in the studies [21-23]. In the 
absence of radiation, SAO:Eu and SAO:Eu@mSiO2 
nanoparticles were not toxic to H1299 cells (Figures 
1e, 2a). The low toxicity of SAO:Eu@mSiO2 was also 
 
Figure 2. X-PDT induced cell death. (a) Cell viability, measured by MTT assays performed 24 h after X-PDT. In control groups, including RT alone and nanoparticles alone, there 
was no significant drop of viability. (b) Cell reproductive capacity, measured by clonogenic assays taken 14 days after X-PDT (* p-value < 0.01). (c) Apoptosis and necrosis assays, 
performed 24 h after X-PDT. Scale bars: 100 µm. 
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observed in our previous studies with other cell lines 
[24] and is not surprising because all the constituents 
of the nanoparticles, including MC540, SAO:Eu, and 
SiO2, are not toxic in the dark [14]. Meanwhile, RT 
alone (0-5 Gy) did not induce significant cell death at 
24 hours either (Figure 2a). As a comparison, when 
X-ray irradiation was applied after 
MC540-SAO:Eu@mSiO2 (50 µg/mL) incubation (i.e. 
X-PDT), there was significant cell viability drop 
(Figure 2a). Specifically, when irradiation of 0.83, 1.67, 
3.33, and 5 Gy was applied, the 24-hour cell viability 
was reduced to 31.4 ± 2.3%, 19.6 ± 4.6%, 18.6 ± 7.4%, 
and 17.5 ± 5.6%, respectively.  
While MTT assay is adequate to measures 
short-term cell viability, it is suboptimal in assessing 
the reproductive capacity of cancer cells. For RT, 
however, reproductive capacity is a more relevant 
ending point. This is because ionizing radiation 
mainly targets DNA, most importantly double-strand 
DNA break [25]. This is often manifested not as 
immediate cell death but reduced clonogenicity in 
days or weeks [26]. To investigate, we performed 
clonogenic assays with H1299 cells that received RT 
alone (0, 1, 2.5, 5, 7.5 and 10 Gy) or RT plus 
MC540-SAO:Eu@mSiO2 (50 μg/mL). X-PDT was 
much more effective than RT alone at all doses (Figure 
2b). Taking 5 Gy for instance, X-PDT was able to 
reduce the survival fraction (SF) to 17.5%, compared 
to that of 42.5% for RT alone. The dose enhancement 
factor (DEF) was calculated to be 1.67 (Methods 
Section).  
Impact of X-PDT on DNA and lipid 
membranes 
To further investigate the cause of X-PDT 
induced cell death, we performed 
Apoptotic/Necrotic/Healthy assay (PromoCell, 
Heidelberg, Germany), again with H1299 cells. With 
RT only (5 Gy), cells showed a mediocre level of 
apoptosis at 24 h but no detectable necrosis (Figure 
2c). On the contrary, when cells were treated with 
MC540-SAO:Eu@mSiO2 (50 µg/mL) plus radiation, 
there manifests extensive cell necrosis (Figure 2c). 
This pattern resembles membrane-targeted PDT, 
which causes oxidative degradation of unsaturated 
lipids and surface proteins [27]. To confirm, we 
conducted lipid peroxidation assay (Lipid 
Peroxidation Kit, Life Technologies, Carlsbad, CA). 
Compared to the control (PBS only), the lipid 
peroxidation level was increased by 90.5 ± 23.0% after 
RT (5 Gy); meanwhile, X-PDT under the same 
irradiation dose led to an increase of 201.5 ± 34.0% 
(Figure 3a). Such lipid peroxidation is attributed 
mainly to the PDT component of X-PDT and is 
responsible for the short-term cell necrosis and 
viability drop.  
 
Figure 3. Impacts of X-PDT on cellular compartments. (a) Lipid damage assessment, measured by lipid peroxidation assays. (b) DNA damage, assessed by single cell 
electrophoresis assays. (c) Western blot assays, which further confirms the impact of X-PDT on DNA and membrane lipids. 
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Meanwhile, X-PDT also causes DNA damage. 
This was confirmed by comet assays in (also known as 
single cell gel electrophoresis assay, Figure 3b). 
Compared to the control, cells received RT alone (5 
Gy) displayed a relatively long and intense tail, 
suggesting extensive DNA double-strand break [28]. 
Such a tail was also observed with X-PDT treated 
cells, but was shorter, less intense, and more discrete, 
likely associated with the extensive necrosis [28]. This 
suggests that there remains a RT component in 
X-PDT, which explains the reduced cell survival in 
clonogenic assays.  
To further assess the cellular impacts of X-PDT, 
we analyzed expression levels of histone H2AX and 
Cox-2 in X-PDT treated H1299 cells with Western blot 
(Figure 3c). Histone H2AX plays a critical role in 
recruiting repair- or damage-signaling factors to the 
sites of DNA damage [29, 30] and is thus an indicator 
of RT-induced DNA breakage. Cox-2, on the other 
hand, is involved in lipid peroxidation, and is often 
up-regulated after PDT-induced membrane damage 
[31, 32]. We found that X-ray radiation (5 Gy) alone 
induced expression of H2AX but minimally affected 
the level of Cox-2 (Figure 3c). With X-PDT, on the 
other hand, both Cox-2 and H2AX expressions were 
increased, although the H2AX level was lower than 
that after RT (Figure 3c). These results corroborate 
with the preceding studies, again confirming that 
X-PDT is essentially a combination of RT and PDT. It 
is postulated that because the two modalities target 
different cellular compartments (DNA and 
unsaturated membrane lipids, respectively), a 
synergy in treatment occurs that leads to much more 
efficient cancer cell killing.  
Impact of tissue depth on the efficacy of 
X-PDT 
We next stdied the impact of tissue thickness on 
the treatment efficacy of X-PDT in vivo. This was first 
studied with mouse subcutaneous tumor models 
established with H1299 cells. Briefly, we 
intratumorally injected MC540-SAO:Eu@mSiO2 
nanoparticles (4.25 mg/kg) to tumor bearing animals; 
we then irradiated the tumors (5 Gy, with the rest of 
the body lead-shielded), with pork tissues of 1- or 
2-cm thickness lain on top. In control group, animals 
were injected with PBS and received no radiation.  
Tumors in the control group grew very rapidly, 
and either died or reached an end point (tumor 
diameter > 1.7 cm) within 10 days (Figure 4a). 
 
 
Figure 4. X-PDT to treat subcutaneously implanted tumors from above thick tissues. (a) Tumor growth curves. Despite of using thick pork as tissue blocks, X-PDT can 
efficiently suppress tumor growth. (b) H&E staining with tumor tissues. X-PDT caused extensive cancer cell death in H1299 tumors. Scale bars, 100 µm. (c) Body weight curves. 
X-PDT did not cause significant changes to the animal body weights. 
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Figure 5. In vivo therapy studies. (a) Representative bioluminescence images of mice treated by X-PDT, RT, MC540-SAO:Eu@mSiO2 and PBS on Day 1, 7, and 12. 
MC540-SAO:Eu@mSiO2 nanoparticles were intrathoracically injected to the mice. In the RT and X-PDT groups, a single dose X-ray radiation of 5 Gy was applied to the tumor 
area, with the rest of the body covered by lead. (b) Tumor growth, measured by monitoring BLI signal changes at different time points. (c) Ex vivo bioluminescence images taken 
immediately after tissue dissection. The organs were organized in the following order: top row (from left to right): intestine, spleen, liver and skin; bottom row (from left to right): 
muscle; brain; lung; heart and kidneys. (d) BLI signals from the lungs. Based on ROI analyses on (c). (e) Representative photographs of lungs taken from the X-PDT and control 
Groups. (f) H&E staining with tumor tissues from different treatment groups. Scale bars, 100 µm. 
 
As a comparison, in all the treatment groups, 
tumor growth was efficiently slowed. On Day 16, the 
tumor suppression rates were 54.2% and 33.8%, for 
the animals bore with 1-, and 2-cm thick pork, 
respectively. The results suggest that tissue thickness 
can still affect the efficacy of X-PDT; the impact, 
however, was much less severe than with PDT, which 
lost its efficacy beyond 1 cm thickness. Such tissue 
impact can likely be compensated by increasing 
radiation doses and is less of a concern in the clinical 
setting, where deep-penetrating megavoltage X-rays 
are used [33]. The efficiency in cancer cell killing was 
further confirmed with H&E analysis (Figure 4b). 
Compared with the control animals, where cancer 
cells were densely packed, X-PDT dramatically 
reduced cell density and disrupted connective tissues 
(Figure 4b). Meanwhile, we observed no signs of 
systematic toxicities to the surrounding tissues 
(Figure 4c).  
Next, we investigated the X-PDT efficacy by 
injecting nanoparticles and cell mixture to the thorax 
of mice and irradiated the injection sites in vivo. Due 
to thick soft tissues and bones, diseases at this 
position are not accessible by conventional PDT [34]. 
Specifically, we injected MC540-SAO:Eu@mSiO2 
nanoparticles (4.25 mg/kg), along with 5 × 105 firefly 
luciferase expressing H1299 cells (H1299-Luc), into 
the left lateral thorax of nude mice (Figure 5a). 
Radiation (5 Gy) was applied to the tumor inoculation 
sites, with the rest of the animal body shielded by 
lead. Control group animals received radiation only 
or PBS only. The tumor growth was then monitored in 
vivo by bioluminescence imaging (BLI). In PBS and 
RT only groups, the BLI signals were detected in the 
lung areas on Day 7 and continued increasing 
afterwards (Figure 5a). In X-PDT treated animals, on 
the other hand, the BLI signals were significantly 
suppressed. By regions of interest (ROI) analysis, on 
Day 12, the average BLI signals were 5.6 × 105, 2.9 × 
106, and 2.6 × 106 photons/sec/cm2/sr for the X-PDT, 
RT, and PBS groups, respectively (Figure 5b). Ex vivo 
imaging confirmed the efficiency of X-PDT induced 
tumor suppression, finding strong residual signals in 
the lungs of control animals but close-to-background 
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signals from the X-PDT group (Figure 5c,d). 
Moreover, we found multiple large tumors in the 
lungs dissected from control animals, but few 
detectable colonies in X-PDT treated mice (Figure 5e). 
Such reduced tumorigenicy by X-PDT was further 
confirmed by H&E staining (Figure 5f).  
Meanwhile, X-PDT did not cause detectable 
systematic toxicities. These include no signs of side 
effects to normal tissues from H&E staining (Figure 
6a). Also, hemodiagnosis found that the serum 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels remained unchanged 
over the course of the treatment, again suggesting low 
toxicities (Figure 6b). This is in accordance with our 
previous observations that i.v. injected 
MC540-SAO:Eu@mSiO2 nanoparticles are degraded 
after the conclusion of therapy and efficiently cleared 
from the hosts [14].  
Discussions  
While initially developed as a PDT derivative, 
the current study suggests that X-PDT is essentially a 
PDT and RT combination. While a portion of X-ray 
energy was converted to activate PDT, ionizing 
radiation continues playing an important role in 
X-PDT. The PDT and RT components target different 
cellular components and the combination causes 
enhanced effect that is beyond the repairs of cells. This 
explains the greater cytotoxicity with X-PDT than 
with RT, especially for cells that are refractory to RT. 
In fact, previous studies have observed synergy 
between PDT and RT [35-38]. However, it was found 
that PDT and ionizing irradiation need to be given at 
the same time so as to override cell repairs [35, 36]. 
This requires photo-irradiation and X-ray irradiation 
to be applied simultaneously, which is difficult to 
achieve in the clinic, not to mention the shallow 
penetration of PDT. X-PDT, on the other hand, is an 
inherent PDT and RT combination, with both 
processes regulated by one deep-penetrating 
radiation. From this perspective, X-PDT represents a 
major advance for seamlessly integrating PDT and 
RT. In this sense, X-PDT should be viewed as not only 
a PDT derivative but also a RT derivative.  
RT remains a major therapy option in clinical 
oncology. More than 50% of all cancer patients receive 
RT during their curative process [39]. One major 
limitation of RT is that not all cancer cells are well 
responsive to RT, and tumors that are originally 
responsive may develop resistance over the course of 
therapy [40]. Increasing radiation doses can, to a 
certain degree, address the issue, but will inevitably 
cause collateral damage to normal tissues [41]. 
Radiosensitizing agents of different types have been 
developed to sensitize cancer cells to RT; however, 
many radiosensitizers are cytotoxic agents [42]. As 
discussed above, X-PDT can be viewed as a RT 
derivative and as such a novel radiosensitizing 
technology. This was confirmed by our clonogenic 
assays, which observed a high DEF with X-PDT, even 
against cells that are refractory to RT. Unlike many 
conventional radiosensitizers, MC540-SAO:Eu@ 
mSiO2 nanoparticles are not toxic in the absence of 
radiation. Meanwhile, they are highly biodegradable, 
efficiently cleared out of the hosts after treatment, and 
causing no side effects to normal tissues (Figure 6). 
These properties suggest great promise of X-PDT in 
clinic translation to improve RT efficacy, reduce 
normal tissue radiation exposure, and battle with 
radioresistant tumors. In the present studies, 
nanoparticles were directly injected into tumors. In 
the future studies, it is worthwhile to reduce 
nanoparticle size, improve photosensitizer loading, 
and conjugating targeting ligands to the nanoparticle 
surface for achieve formulations that can be 
systematically injected to mediate tumor selective 
X-PDT treatment.  
 
 
Figure 6. Systematic toxicities of X-PDT. (a) H&E staining with normal tissues taken from X-PDT, RT, MC540-SAO:Eu@mSiO2, and control groups. Scale bars, 100 µm. (b) 
Hemodiagnosis. ALT and AST level showed no significant changes before and 14 days after X-PDT treatment. 
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Conclusion 
In summary, we investigated in this study the 
impacts of X-PDT on cancer cells. We found that 
X-PDT is not simply a PDT process; rather, it is 
essentially a RT and PDT combination. The 
combination leads to enhanced therapy effects that 
make the treatment much more efficient than RT 
alone, even when used against cells that are refractory 
to RT. We also show that X-PDT can be exploited to 
suppress tumors lain under deep tissues. The findings 
and advances are of great value to the developments 
of X-PDT as a novel treatment modality against 
cancer.  
Materials and Methods 
Nanoparticle synthesis and coating SAO:Eu 
was synthesized by a carbo-thermal reduction and 
vapor-phase deposition method that was published 
previously [43]. To render SAO:Eu amenable to 
bio-related applications, bulk SAO:Eu was ground 
into nanoparticles with a diameter of ~ 80 nm. The 
bare SAO:Eu nanoparticles were coated with a layer 
of solid silica by following a previously published 
protocol [14]. In a typical synthesis, 10 mg of SAO:Eu 
nanoparticles were dispersed in a mixture of 25 mL of 
ethanol, 2 mL of H2O, and 1 mL of ammonia (25%), 
and stirred for 10 min. Then, 75 µL of tetraethyl 
orthosilicate (TEOS) was added to solution and the 
mixture was stirred at room temperature for 12 hours. 
The resulting nanoparticles were subsequently coated 
with a layer of mesoporous silica. A mixture of 
3-aminopropyltriethoxysilane and TEOS (5 v/v%) 
was used as silane precursors [24]. Solid silica coated 
SAO:Eu nanoparticles (10 mg) from the first step were 
dispersed in a mixture of 45 mL of H2O, 0.3 mL of 2 M 
NaOH, and 10 mg of cetyltrimethylammonium 
bromide (CTAB) for 30 min. After heating to 70 oC, 50 
µL of TEOS and 300 µL of ethyl acetate were added, 
and the solution was magnetically stirred for 2 h. The 
raw products were collected by centrifugation and 
washed with ethanol for three times. The resulting 
nanoparticles were re-suspended in ethanol (20 mL) 
and mixed with NH4NO3 (100 mg) at 60 oC for 2 hours 
to remove CTAB. For photosensitizer loading, MC540 
(Invitrogen) were dispersed in ethanol with 
SAO:Eu@mSiO2 nanoparticles. The mixture was 
incubated overnight at room temperature [14]. After 
centrifuging and washing several times, and the 
supernatant removed. The MC540-loaded 
nanoparticles were resuspended in PBS (Thermo 
Scientific) for further studies. 
Characterizations of SAO:Eu and MC540-SAO: 
Eu@mSiO2 nanoparticles. UV-Vis absorption spectra 
were recorded on a Shimdzu 2450 UV-Vis 
spectrometer. Photoluminescence measurements 
were performed on a Hitachi F-7000 fluorometer. A 
mini-X X-ray tube (Amptek Inc.) was used as the 
X-ray source, and was set at 50 kV and 70 μI for all the 
experiments in this study. TEM samples were 
prepared by dripping sample solutions onto 
carbon-coated copper grids and evaporating the 
solvent. TEM images were taken on an FEI Tecnai 20 
transmission electron microscope operating at 200 kV. 
Cell culture H1299, a human NSCLC cell line, 
was used in in vitro and in vivo studies. The H1299 
cells have been transfected to stably express firefly 
luciferase (i.e. H1299-Luc). The cells had been tested 
and were rodent pathogens free. H1299-Luc cells were 
grown in RPMI 1640 medium supplemented with 10% 
FBS, 100 units/mL of penicillin (ATCC) and 250 
µg/mL hygromycin. The cells were maintained in a 
humidified, 5 % carbon dioxide (CO2) atmosphere at 
37 °C.  
In vitro toxicity study 104 H1299 cells were 
seeded in 96-well plates (Corning) and cultured to 
90% confluency. For cytotoxicity studies, the cells 
were then incubated with 0, 5, 10, 25, 50 and 100 
μg/mL MC540-SAO:Eu@mSiO2 nanoparticles for 24 
h. Subsequently, they were washed with PBS for two 
times, and then were evaluated by MTT assay (Sigma 
Aldrich) by following the vendor’s protocols.  
In vitro viability study. 104 H1299 cells were 
seeded in 96-well plates (Corning) and cultured for 24 
h. The cells were then divided into 5 groups: 1) PBS 
group, 2) MC540-SAO:Eu@mSiO2 nanoparticles only, 
3) MC540 only, 4) RT only, and 5) X-PDT. For Group 2 
and 5, the final concentration of 
MC540-SAO:Eu@mSiO2 nanoparticles was 50 μg/mL 
and the incubation time was 1 hour. All the cells were 
incubated in the dark. Cells in Group 4 and 5 were 
irradiated with 50 kV X-ray at 0.83, 1.67, 3.33 and 5 Gy 
while all the other cells received irradiation. After the 
treatment, all cells were washed with PBS for two 
times. Cell culture medium was replenished and the 
incubation was maintained for 24 h (5 % CO2 and 37 
°C). Cell viabilities were evaluated by MTT assays 
(Sigma Aldrich) following the vendor’s protocol.  
Apoptosis/necrosis/healthy assay H1299-Luc 
cells treated with X-PDT (5 Gy), RT (5 Gy) and PBS 
were subjected to Apoptotic/Necrotic/Healthy assay 
(PromoCell GmbH, Heidelberg, Germany) following 
the vendor’s protocol. Briefly, FITC-annexin V (green) 
binds to the apoptosis marker of phosphatidyl serine, 
and ethidium homodimer III (red) binds to DNA 
under the necrotic conditions. The cells stained with 
annexin V antibody alone or together with ethidium 
homodimer III were counted as early or late stages of 
apoptotic cells, respectively [34]. The cells labeled 
with ethidium homodimer III alone were counted as 
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necrotic cells. In addition, membrane permeable 
Hoechst 33342 (blue) stains the nuclei. Healthy cells 
would only display blue staining. The resulted cells 
were then evaluated by fluorescent imaging on an 
Olympus IX71 fluorescent microscope (3 trials per 
group). 
Clonogenic assay Mono-layered H1299-Luc cells 
were prepared in 6-well cell petri-dishes one day 
before the experiments. On the experimental day, the 
6-well cell petri-dishes were randomly divided into 
the control group, the X-ray radiation group, and the 
X-PDT group. The two treatment groups were treated 
by X-ray (50 kv) for a dose of 1, 2.5, 5, 7.5 and 10 Gy 
while the control group received no irradiation. The 
irradiated and un-treated cells were then harvested 
using trypsin-EDTA and plated into 100 mm cell 
petri-dishes. Each petri-dish was seeded with 100 
viable cells and was placed into a cell culture 
incubator (5% CO2 and 37°C) for 14 days. After 
incubation for 14 days, the cells were fixed by 
formalin and stained with 0.5% Gentian Violet. 
Colonies containing more than 50 cells were counted 
and the survival fractions were calculated by 
comparing to the control. Dose enhancement factor 
(DEF) was calculated as the ratio between RT and 
X-PDT radiation doses at 10% survival fractions. All 
the experiments were repeated 3 times.  
Lipid peroxidation assay Lipid peroxidation 
levels were measured using Image-iT® Lipid 
Peroxidation Kit (Life Technologies Corporation, 
Carlsbad, CA) by following the vendor’s protocol. 
Briefly, H1299-Luc cells seeded in 6-well petri-dishes 
were treated with RT or X-PDT under 5 Gy X-ray 
irradiation. Un-irradiated cells were used as control. 
The Image-iT reagent was incubated with cells for 30 
min. The cells were washed three times with PBS and 
observed on an Olympus IX71 fluorescence 
microscope. Data were analyzed by ImageJ (NIH, 
Bethesta, Maryland, U.S.). The experiments were 
repeated 5 times.  
Single cell gel electrophoresis (comet assay) 
Mono-layered cells were prepared in 6-well cell 
petri-dishes one day before the experiments. On the 
experimental day, the 6-well cell petri-dishes were 
randomly divided into the control group, the X-ray 
radiation group, and the X-PDT (with 
MC540-SAO:Eu@mSiO2) group. Then the two 
treatment groups were irradiated by X-ray (50 kV) for 
a dose of 5 Gy while the control group received 0 dose 
irradiation. The irradiated and un-treated cells were 
then harvested. 1 × 105/mL of the treated cells were 
immediately combined with molten LMAgarose (at 
37°C) at a ratio of 1:10 (v/v). 50 μL of the solution was 
pipetted onto a CometSlide™ (Trevigen Inc., 
Gaithersburg, MD). The slide was then immersed in 
4°C lysis solution for 1 hour or overnight. After that, 
~850 ml 4°C 1× neutral electrophoresis buffer was 
added to the electrophoresis gel box and the slides 
were placed in a slide tray. The power supply was set 
at 21 volts. After 45 minutes, the slides were gently 
removed and immersed in DNA Precipitation 
Solution for 30 minutes, and then in 70% ethanol for 
30 minutes at room temperature. The slides were 
dried and stained in SYBR® safe for 30 min in the 
dark. The slides were then ready for microscopic 
imaging.  
Western blot Approximately 5 × 105 H1299-Luc 
cells were seeded in a 6-well plate prior to radiation 
therapy. Cells were harvested 1 hours and 24 hours 
after the treatment. The cells were lysed in a lysis 
buffer. Proteins were separated by pre-cast 12% 
Bis-Tris NuPageTM SDS-PAGE (Life SciencesTM), 
transferred to iBlot® polyvinylidene difluoride 
membrane (InvitrogenTM, Grand Island, NY, USA), 
and immunoblotted using primary antibodies against 
COX2, H2AX, and β-actin. HRP-conjugated 
secondary antibody (Cell Signaling Technology, 
Danvers, MA, USA) was applied subsequently. The 
protein bands were then visualized with 
SuperSignal™ West Pico Chemiluminescent Substrate 
(Thermo Fisher Scientific) using a Fluorchem HD2 
chemiluminescent imaging system (Protein Simple, 
Santa Clara, CA).  
Animal studies All the animal studies 
conformed to the Guide for the Care and Use of 
Laboratory Animals published by the National 
Institutes of Health, USA, and a protocol approved by 
the Institutional Animal Care and Use Committee 
(IACUC), University of Georgia. Nude mice (4–6 
weeks old, Harlan) with a body weight of ~20 g were 
used for the animal model establishment. The animals 
were housed in alternating lighting conditions under 
a 12 h dark and 12 h light regime. 
Therapy studies with subcutaneous tumor 
models 15 nude 5−6 week athymic nude mice were 
randomly divided into three groups, 1) control group, 
2) 1-cm thick pork group, and 3) 2-cm thick pork 
group. Animal models were established by 
subcutaneous injection of 5 × 105 H1299-Luc tumor 
cells onto the hind legs of mice. When tumor sizes 
reached 100 nm, 100 μL PBS solution containing 
MC540-SAO:Eu@mSiO2 nanoparticles (4.25 mg/kg) 
was intratumorally injected in Group 2 and 3. The 
same amount of PBS was injected into the tumors of 
the control group. For therapy studies, irradiation (5 
Gy) was applied to tumors, with the rest of the animal 
body covered by lead. The control group received no 
irradiation.  
Therapy studies with cancer cells implanted 
into the lungs 20 nude mice were randomized to 
 Theranostics 2016, Vol. 6, Issue 13 
 
http://www.thno.org 
2304 
receive the following treatments group (n = 5): 1) PBS, 
2) MC540-SAO:Eu@mSiO2 only, 3) RT only, and 4) 
X-PDT (MC540-SAO:Eu@mSiO2 plus RT). 5 × 
105 H1299-Luc cells were injected into the left lateral 
thorax of anesthetized nude mice. For Group 1 and 3, 
PBS solution was premixed with the cells into a final 
volume of 50 µL. For group 2 and 4, nanoparticles were 
premixed with cells into a final volume 50 µL matrigel 
solutions (2.5 mg MC540-SAO:Eu@mSiO2/mL, or 1.7 
mg SAO:Eu/mL). Group 1 and 2 received no X-ray 
irradiation. Group 3 and group 4 received X-ray 
irradiation (5 Gy) 5 minutes after the injection. Only 
one therapy dose was given to each animal. The 
tumor growth was monitored BLI by an IVIS Lumina 
scanner (PerkinElmer Inc. Waltham, Massachusetts). 
Tumors and major organs from the euthanized 
animals were harvested, weighed, and cryosectioned. 
The tissue sections were then subjected to standard 
H&E staining to assess treatment outcomes and side 
effects (BBC Biochemical). Hemodiagnosis assay was 
performed by withdrawing the blood before the 
treatment as well as before euthanizing the mice. The 
concentrations of AST and ALT were determined by 
using commercial kits from Thermo-Scientific. 
Statistical analyses Quantitative data were 
expressed as mean ± s.e.m. A two-tailed Student’s 
t-test was used for statistically comparing the 
treatment group and the control group. P < 0.05 was 
considered statistically significant. 
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